Inventiva: last NATiV3 patient completes 72 weeks; lanifibranor topline on track for Q4 2026

Inventiva/Lanifibranor

On its Q2 2026 call, Inventiva said the final NATiV3 patient finished the 72-week visit in September and topline results remain due in Q4 2026. If positive, it plans a US filing in the first half of 2027 for accelerated approval, conditional approval in Europe, and an outcomes trial in cirrhosis. The company holds €233.9M in cash, enough into Q2 2027.

• Primary endpoint: MASH resolution plus one-stage fibrosis improvement in the same patient; 90% power on conservative assumptions.
• Phase 2b NATIVE (6 months): placebo-adjusted +18% fibrosis, +26% MASH resolution, +24% composite.
• Exploratory cohort includes roughly 75–100 cirrhotic patients treated at least 18 months.
• Possible US launch in 2028.